Hong-Min Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/847931/publications.pdf

Version: 2024-02-01

189 papers 4,747 citations

109264 35 h-index 55 g-index

197 all docs

197
docs citations

197 times ranked

4570 citing authors

#	Article	IF	CITATIONS
1	Investigating the binding mechanism of piperidinyl ureas inhibitors based on the UBC12-DCN1 interaction by 3D-QSAR, molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2022, 40, 2674-2688.	2.0	2
2	An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 9-25.	0.8	7
3	Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis. Acta Pharmaceutica Sinica B, 2022, 12, 291-307.	5.7	8
4	Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy. European Journal of Medicinal Chemistry, 2022, 227, 113967.	2.6	9
5	Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer. European Journal of Pharmacology, 2022, 916, 174725.	1.7	4
6	Synthesis, biological evaluation and cellular localization study of fluorescent derivatives of Jiyuan Oridonin A. European Journal of Medicinal Chemistry, 2022, 229, 114048.	2.6	1
7	Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 2022, 12, 2193-2205.	5.7	26
8	Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors. European Journal of Medicinal Chemistry, 2022, 230, 114106.	2.6	5
9	Magnolol-loaded cholesteryl biguanide conjugate hydrochloride nanoparticles for triple-negative breast cancer therapy. International Journal of Pharmaceutics, 2022, 615, 121509.	2.6	8
10	Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects. Journal of Medicinal Chemistry, 2022, 65, 163-190.	2.9	4
11	SDC: An integrated database for sex differences in cancer. Computational and Structural Biotechnology Journal, 2022, 20, 1068-1076.	1.9	O
12	LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Molecular Cancer, 2022, 21, 75.	7.9	54
13	Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharmaceutica Sinica B, 2022, 12, 3263-3280.	5.7	11
14	KDM1A/LSD1 as a promising target in various diseases treatment by regulating autophagy network. Biomedicine and Pharmacotherapy, 2022, 148, 112762.	2.5	8
15	Identification of the upstream regulators of KDM5B in gastric cancer. Life Sciences, 2022, 298, 120458.	2.0	6
16	A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114564.	2.6	14
17	A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. Acta Pharmaceutica Sinica B, 2021, 11, 750-762.	5.7	23
18	Discovery of thiosemicarbazone derivatives as effective New Delhi metallo- $\hat{1}^2$ -lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates. Acta Pharmaceutica Sinica B, 2021, 11, 203-221.	5.7	45

#	Article	lF	CITATIONS
19	Chemical molecularâ€based approach to overcome multidrug resistance in cancer by targeting Pâ€glycoprotein (Pâ€gp). Medicinal Research Reviews, 2021, 41, 525-555.	5.0	150
20	Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica B, 2021, 11, 694-707.	5.7	56
21	Gramine-based structure optimization to enhance anti-gastric cancer activity. Bioorganic Chemistry, 2021, 107, 104549.	2.0	11
22	Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacological Research, 2021, 164, 105335.	3.1	44
23	Pd(II)-Catalyzed Intramolecular C(sp ²)â€"H Arylation of Tryptamines Using the Nonsteric NH ₂ as a Directing Group. Organic Letters, 2021, 23, 42-48.	2.4	8
24	Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells. European Journal of Medicinal Chemistry, 2021, 210, 112970.	2.6	18
25	Microbial profiling identifies potential key drivers in gastric cancer patients. Biotechnology and Biotechnological Equipment, 2021, 35, 496-503.	0.5	4
26	Novel strains with superior degrading efficiency for lincomycin manufacturing biowaste. Ecotoxicology and Environmental Safety, 2021, 209, 111802.	2.9	15
27	Antiviral Activity of 3D, a Butene Lactone Derivative Against Influenza A Virus In Vitro and In Vivo. Viruses, 2021, 13, 278.	1.5	3
28	Discovery of $[1,2,4]$ triazolo $[1,5-a]$ pyrimidines derivatives as potential anticancer agents. European Journal of Medicinal Chemistry, 2021, 211, 113108.	2.6	14
29	Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1. Journal of Medicinal Chemistry, 2021, 64, 2466-2488.	2.9	48
30	A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. Journal of Medicinal Chemistry, 2021, 64, 1362-1391.	2.9	73
31	Cu(OTf) ₂ -Catalyzed Intramolecular Radical Cascade Reactions for the Diversity-Oriented Synthesis of Quinoline-Annulated Polyheterocyclic Frameworks. Organic Letters, 2021, 23, 1445-1450.	2.4	17
32	Synthesis of Natural Product-Like Tricyclic Higher-Carbon Sugar Nucleosides. Pharmaceutical Fronts, 2021, 03, e18-e22.	0.4	0
33	LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor. Journal of Oncology, 2021, 2021, 1-11.	0.6	13
34	Targeting neddylation E2s: a novel therapeutic strategy in cancer. Journal of Hematology and Oncology, 2021, 14, 57.	6.9	23
35	Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. Bioorganic Chemistry, 2021, 109, 104754.	2.0	4
36	Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction. European Journal of Medicinal Chemistry, 2021, 217, 113326.	2.6	7

#	Article	IF	CITATIONS
37	Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. EMBO Reports, 2021, 22, e50922.	2.0	20
38	Design and synthesis of new indole containing biaryl derivatives as potent antiproliferative agents. Bioorganic Chemistry, 2021, 110, 104821.	2.0	4
39	Myofibroblast Deficiency of LSD1 Alleviates TAC-Induced Heart Failure. Circulation Research, 2021, 129, 400-413.	2.0	27
40	Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127993.	1.0	6
41	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. European Journal of Medicinal Chemistry, 2021, 218, 113392.	2.6	15
42	Identification of ferroptosis as a novel mechanism for antitumor activity of natural product derivative a2 in gastric cancer. Acta Pharmaceutica Sinica B, 2021, 11, 1513-1525.	5.7	42
43	Cullin-RING Ligases as Promising Targets for Gastric Carcinoma Treatment. Pharmacological Research, 2021, 170, 105493.	3.1	8
44	Jaridon 6, a new diterpene from <i>Rabdosia rubescens</i> (Hemsl.) Hara, can display antiâ€gastric cancer resistance by inhibiting <scp>SIRT1</scp> and inducing autophagy. Phytotherapy Research, 2021, 35, 5720-5733.	2.8	3
45	Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway. Bioorganic and Medicinal Chemistry, 2021, 43, 116265.	1.4	9
46	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. Experimental Cell Research, 2021, 405, 112728.	1.2	8
47	CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). Biochemical Pharmacology, 2021, 190, 114652.	2.0	5
48	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 14895-14911.	2.9	27
49	Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment. Bioorganic and Medicinal Chemistry, 2021, 45, 116331.	1.4	10
50	Design, synthesis and antitumor activity evaluation of trifluoromethyl-substituted pyrimidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2021, 51, 128268.	1.0	8
51	Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment. European Journal of Medicinal Chemistry, 2021, 226, 113896.	2.6	4
52	Establishment of high-throughput screening HTRF assay for identification small molecule inhibitors of Skp2-Cks1. Scientific Reports, 2021, 11, 21105.	1.6	3
53	Discovery of the Triazolo $[1,5-\langle i\rangle a\langle i\rangle]$ Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. Journal of Medicinal Chemistry, 2021, 64, 16187-16204.	2.9	14
54	Systematic Review and Meta-Analysis of Lysine-Specific Demethylase 1 Expression as a Prognostic Biomarker of Cancer Survival and Disease Progression. Cancer Control, 2021, 28, 107327482110515.	0.7	2

#	Article	IF	CITATIONS
55	Screening and pharmacodynamic evaluation of the antiâ€respiratory syncytial virus activity of butene lactones in vitro and in vivo. Journal of Medical Virology, 2020, 92, 17-25.	2.5	3
56	BrÃ,nsted acid-promoted â€~on–water' C(sp3)-H functionalization for the synthesis of isoindolinone/[1,2,4]triazolo[1,5-a]pyrimidine derivatives targeting the SKP2-CKS1 interaction. Chinese Chemical Letters, 2020, 31, 349-352.	4.8	20
57	Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors. Chinese Chemical Letters, 2020, 31, 418-422.	4.8	21
58	Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors. Acta Pharmaceutica Sinica B, 2020, 10, 1476-1491.	5.7	37
59	Development of a mass spectrometry-based pseudotargeted metabolomics strategy to analyze hormone-stimulated gastric cancer cells. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113041.	1.4	13
60	Expression of programmed death ligand $1\ (PD-L1)$ is associated with metastasis and differentiation in gastric cancer. Life Sciences, 2020, 242, 117247 .	2.0	18
61	Synthesis and inÂvitro and inÂvivo biological evaluation of novel derivatives of flexicaulin A as antiproliferative agents. European Journal of Medicinal Chemistry, 2020, 208, 112789.	2.6	2
62	Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy. European Journal of Medicinal Chemistry, 2020, 203, 112601.	2.6	9
63	Discovery of new [1,2,4] Triazolo[1,5-a]Pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway. European Journal of Medicinal Chemistry, 2020, 203, 112630.	2.6	14
64	Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents inÂvitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway. European Journal of Medicinal Chemistry, 2020, 203, 112618.	2.6	42
65	Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors. European Journal of Medicinal Chemistry, 2020, 191, 112107.	2.6	30
66	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- <i>a</i>)Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. Journal of Medicinal Chemistry, 2020, 63, 15979-15996.	2.9	25
67	Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. European Journal of Medicinal Chemistry, 2020, 204, 112657.	2.6	33
68	New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry, 2020, 205, 112667.	2.6	36
69	Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective. Journal of Medicinal Chemistry, 2020, 63, 14197-14215.	2.9	57
70	Synthesis of new tetracyclic benzodiazepine-fused isoindolinones using recyclable mesoporous silica nanoparticles. Chemical Communications, 2020, 56, 11461-11464.	2.2	13
71	Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing hydrazone fragment as potent and selective anticancer agents. Bioorganic Chemistry, 2020, 105, 104424.	2.0	8
72	Skp2 in the ubiquitinâ€proteasome system: A comprehensive review. Medicinal Research Reviews, 2020, 40, 1920-1949.	5.0	64

#	Article	IF	CITATIONS
73	HFIP-promoted catalyst-free cascade reactions for the synthesis of biologically relevant 3,3-di(indolyl)indolin-2-ones from indoles and isatins. Chinese Chemical Letters, 2020, 31, 2465-2468.	4.8	15
74	LSD1 deletion represses gastric cancer migration by upregulating a novel miR-142-5p target protein CD9. Pharmacological Research, 2020, 159, 104991.	3.1	16
75	The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader. European Journal of Medicinal Chemistry, 2020, 204, 112512.	2.6	16
76	Drug repurposing: Discovery of troxipide analogs as potent antitumor agents. European Journal of Medicinal Chemistry, 2020, 202, 112471.	2.6	11
77	Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation. Bioorganic Chemistry, 2020, 97, 103648.	2.0	37
78	Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2020, 192, 112153.	2.6	9
79	Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B). European Journal of Medicinal Chemistry, 2020, 192, 112161.	2.6	25
80	Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors. Acta Pharmaceutica Sinica B, 2020, 10, 1658-1668.	5.7	24
81	Palladium-Catalyzed Ligand-Free Double Cyclization Reactions for the Synthesis of 3-(1′-Indolyl)-phthalides. Organic Letters, 2020, 22, 814-817.	2.4	19
82	Involvement of Glutathione Depletion in Selective Cytotoxicity of Oridonin to p53-Mutant Esophageal Squamous Carcinoma Cells. Frontiers in Oncology, 2020, 9, 1525.	1.3	21
83	Thiosemicarbazone-based lead optimization to discover high-efficiency and low-toxicity anti-gastric cancer agents. European Journal of Medicinal Chemistry, 2020, 199, 112349.	2.6	8
84	Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters. European Journal of Medicinal Chemistry, 2020, 200, 112458.	2.6	31
85	Role of Drug-metabolizing Enzymes in Cancer and Cancer Therapy. Current Drug Metabolism, 2020, 21, 67-76.	0.7	2
86	Investigating the binding mechanism of (4-Cyanophenyl)glycine derivatives as reversible LSD1 by 3D-QSAR, molecular docking and molecular dynamics simulations. Journal of Molecular Structure, 2019, 1175, 698-707.	1.8	15
87	Discovery and SAR Research for Antivirus Activity of Novel Butenolide on Influenza A Virus H1N1 In Vitro and In Vivo. ACS Omega, 2019, 4, 13265-13269.	1.6	11
88	"Onâ€Water―Palladiumâ€Catalyzed Tandem Cyclization Reaction for the Synthesis of Biologically Relevant 4â€Arylquinazolines. Chemistry - A European Journal, 2019, 25, 13109-13113.	1.7	8
89	Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta Pharmaceutica Sinica B, 2019, 9, 1193-1203.	5.7	19
90	Synthesis and anti-gastric cancer activity evaluation of novel triazole nucleobase analogues containing steroidal/coumarin/quinoline moieties. European Journal of Medicinal Chemistry, 2019, 181, 111520.	2.6	28

#	Article	IF	Citations
91	Purification, structural characterization and anti-UVB irradiation activity of an extracellular polysaccharide from Pantoea agglomerans. International Journal of Biological Macromolecules, 2019, 137, 1002-1012.	3.6	16
92	Novel thiosemicarbazone derivatives containing indole fragment as potent and selective anticancer agent. European Journal of Medicinal Chemistry, 2019, 184, 111764.	2.6	37
93	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. European Journal of Pharmacology, 2019, 863, 172611.	1.7	22
94	Synthesis and inÂvitro biological evaluation of novel derivatives of Flexicaulin A condensation with amino acid trifluoroacetate. European Journal of Medicinal Chemistry, 2019, 182, 111645.	2.6	7
95	Novel tertiary sulfonamide derivatives containing benzimidazole moiety as potent anti-gastric cancer agents: Design, synthesis and SAR studies. European Journal of Medicinal Chemistry, 2019, 183, 111731.	2.6	28
96	Simultaneous determination of 24 free amino acids in MGC803 cells by hydrophilic interaction liquid chromatography with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1132, 121792.	1.2	7
97	Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors. European Journal of Medicinal Chemistry, 2019, 166, 432-444.	2.6	34
98	Design, synthesis and biological evaluation of new steroidal \hat{l}^2 -triazoly enones as potent antiproliferative agents. Steroids, 2019, 150, 108431.	0.8	9
99	Pharmacoepigenetics of LSD1 Inhibitors in Cancer. , 2019, , 523-530.		7
100	Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1–UBE2M Interaction. Journal of Medicinal Chemistry, 2019, 62, 5382-5403.	2.9	34
101	Potent and specific MTH1 inhibitors targeting gastric cancer. Cell Death and Disease, 2019, 10, 434.	2.7	25
102	Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors. European Journal of Medicinal Chemistry, 2019, 175, 357-372.	2.6	28
103	IL33 attenuates ventricular remodeling after myocardial infarction through inducing alternatively activated macrophages ethical standards statement. European Journal of Pharmacology, 2019, 854, 307-319.	1.7	11
104	Discovery of the theobromine derivative MQS-14 that induces death of MGC-803 cells mainly through ROS-mediated mechanisms. European Journal of Medicinal Chemistry, 2019, 174, 76-86.	2.6	7
105	Sanggenon O induced apoptosis of A549 cells is counterbalanced by protective autophagy. Bioorganic Chemistry, 2019, 87, 688-698.	2.0	5
106	Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-⟨i⟩a⟨/i⟩]pyrimidine-Based Inhibitors Targeting the DCN1–UBC12 Protein–Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 2772-2797.	2.9	59
107	Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors. European Journal of Medicinal Chemistry, 2019, 167, 388-401.	2.6	47
108	Targeting the DCN1â€"UBC12 proteinâ€"protein interaction: novel approaches and future directions. Future Medicinal Chemistry, 2019, 11, 2869-2871.	1.1	1

#	Article	IF	CITATIONS
109	Development of formaldehyde dehydrogenase-coupled assay and antibody-based assays for ALKBH5 activity evaluation. Journal of Pharmaceutical and Biomedical Analysis, 2019, 162, 9-15.	1.4	12
110	Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3482-3495.	2.0	16
111	Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors. European Journal of Medicinal Chemistry, 2019, 162, 555-567.	2.6	20
112	Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor. Bioorganic Chemistry, 2019, 84, 164-169.	2.0	38
113	Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Acta Pharmaceutica Sinica B, 2019, 9, 794-808.	5.7	67
114	Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent anti-gastric cancer agents: Design, synthesis and structural optimization. European Journal of Medicinal Chemistry, 2019, 161, 493-505.	2.6	8
115	Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening. Journal of Biomolecular Structure and Dynamics, 2019, 37, 4200-4214.	2.0	5
116	Brønsted Acidâ€Catalyzed Direct C(<i>>sp</i> ²)â^H Heteroarylation Enabling the Synthesis of Structurally Diverse Biaryl Derivatives. Advanced Synthesis and Catalysis, 2019, 361, 59-66.	2.1	19
117	Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target. European Journal of Medicinal Chemistry, 2019, 161, 131-140.	2.6	41
118	USP28 contributes to the proliferation and metastasis of gastric cancer. Journal of Cellular Biochemistry, 2019, 120, 7657-7666.	1.2	19
119	Multiclass analysis of 25 veterinary drugs in milk by ultra-high performance liquid chromatography-tandem mass spectrometry. Food Chemistry, 2018, 257, 259-264.	4.2	57
120	Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents. European Journal of Medicinal Chemistry, 2018, 151, 327-338.	2.6	7
121	Potent hydrazone derivatives targeting esophageal cancer cells. European Journal of Medicinal Chemistry, 2018, 148, 359-371.	2.6	26
122	Lysineâ€specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGCâ€803. Journal of Cellular Biochemistry, 2018, 119, 4957-4966.	1.2	12
123	A Practical and Efficient Stereoselective Synthesis of (S)â€Rivastigmine and (R)â€Rivastigmine. ChemistrySelect, 2018, 3, 1385-1387.	0.7	3
124	Design, synthesis and inÂvitro biological evaluation of novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing a thiosemicarbazide moiety. European Journal of Medicinal Chemistry, 2018, 146, 147-156.	2.6	27
125	Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents. European Journal of Medicinal Chemistry, 2018, 145, 11-22.	2.6	34
126	Generation and characterization of a paclitaxel-resistant human gastric carcinoma cell line. Anti-Cancer Drugs, 2018, 29, 491-502.	0.7	9

#	Article	IF	Citations
127	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2018, 143, 1535-1542.	2.6	41
128	Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles. European Journal of Medicinal Chemistry, 2018, 143, 1489-1509.	2.6	40
129	Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives. European Journal of Medicinal Chemistry, 2018, 143, 1396-1405.	2.6	9
130	Design, synthesis and biological mechanisms research on 1,2,3-triazole derivatives of Jiyuan Oridonin A. Bioorganic and Medicinal Chemistry, 2018, 26, 4761-4773.	1.4	27
131	Design, synthesis and preliminary biological evaluation of 5,8-dihydropteridine-6,7-diones that induce apoptosis and suppress cell migration. European Journal of Medicinal Chemistry, 2018, 143, 1959-1967.	2.6	10
132	Probing the binding mode and unbinding mechanism of LSD1 inhibitors by combined computational methods. Physical Chemistry Chemical Physics, 2018, 20, 29833-29846.	1.3	1
133	Early emergence of OXA-181-producing Escherichia coli ST410 in China. Journal of Global Antimicrobial Resistance, 2018, 15, 215-218.	0.9	15
134	Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy. Bioorganic and Medicinal Chemistry, 2018, 26, 6000-6014.	1.4	31
135	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. Journal of Medicinal Chemistry, 2018, 61, 5988-6001.	2.9	53
136	Targeting Brd4 for cancer therapy: inhibitors and degraders. MedChemComm, 2018, 9, 1779-1802.	3.5	109
137	Simultaneous determination of the novel anti-tumor candidate drug MDH-7 and 5-fluorouracil in rat plasma by LC-MS/MS: Application to pharmacokinetic interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1095, 235-240.	1.2	6
138	Structure of tRNA-Modifying Enzyme TiaS and Motions of Its Substrate Binding Zinc Ribbon. Journal of Molecular Biology, 2018, 430, 4183-4194.	2.0	2
139	Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents. European Journal of Medicinal Chemistry, 2018, 157, 1249-1263.	2.6	29
140	Discovery of a non-toxic [1,2,4]triazolo [1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). Bioorganic and Medicinal Chemistry, 2018, 26, 5006-5017.	1.4	17
141	Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells. International Journal of Molecular Medicine, 2017, 39, 645-653.	1.8	2
142	Jesridonin in combination with paclitaxel demonstrates synergistic anti-tumor activity in human esophageal carcinoma cells. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2058-2062.	1.0	3
143	Discovery of [1,2,3]Triazolo[4,5- <i>d</i>]pyrimidine Derivatives as Novel LSD1 Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 384-389.	1.3	66
144	Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy. European Journal of Medicinal Chemistry, 2017, 135, 204-212.	2.6	32

#	Article	IF	Citations
145	Design, synthesis, and biological evaluation of new thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents. MedChemComm, 2017, 8, 1655-1658.	3.5	7
146	3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3521-3528.	1.0	16
147	OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma. Biochemical Pharmacology, 2017, 140, 16-27.	2.0	19
148	LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1. Pharmacological Research, 2017, 122, 66-77.	3.1	31
149	Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5036-5039.	1.0	26
150	Thiosemicarbazone-based selective proliferation inactivators inhibit gastric cancer cell growth, invasion, and migration. MedChemComm, 2017, 8, 2173-2180.	3.5	14
151	Design, synthesis and preliminary antiproliferative activity studies of new diheteroaryl thioether derivatives. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4377-4382.	1.0	9
152	Design, synthesis and preliminary biological evaluation of new [1,2,3]triazolo[4,5-d]pyrimidine/thiourea hybrids as antiproliferative agents. European Journal of Medicinal Chemistry, 2017, 139, 741-749.	2.6	18
153	A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells. Scientific Reports, 2017, 7, 9873.	1.6	42
154	Synthesis, Cytotoxic Activity Evaluation of Novel 1,2,3â€Triazole Linked Quinazoline Derivatives. Chinese Journal of Chemistry, 2017, 35, 1633-1639.	2.6	16
155	Design, synthesis and antiproliferative activity of thiazolo[5,4-d]pyrimidine derivatives through the atom replacement strategy. European Journal of Medicinal Chemistry, 2017, 138, 1034-1041.	2.6	9
156	Gene expression profiling and pathway network analysis of anti-tumor activity by Jaridon 6 in esophageal cancer. European Journal of Pharmacology, 2017, 815, 478-486.	1.7	8
157	Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers. European Journal of Medicinal Chemistry, 2017, 138, 1076-1088.	2.6	35
158	Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 940-951.	2.6	65
159	Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation. European Journal of Medicinal Chemistry, 2017, 126, 246-258.	2.6	56
160	Pro-Apoptotic Effects of JDA-202, a Novel Natural Diterpenoid, on Esophageal Cancer Through Targeting Peroxiredoxin I. Antioxidants and Redox Signaling, 2017, 27, 73-92.	2.5	21
161	An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors. Current Medicinal Chemistry, 2017, 24, 2496-2504.	1.2	18
162	Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway. Oncotarget, 2016, 7, 72990-73002.	0.8	57

#	Article	IF	CITATIONS
163	Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach. European Journal of Medicinal Chemistry, 2016, 117, 241-255.	2.6	68
164	TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Epigenomics, 2016, 8, 651-666.	1.0	72
165	Synthesis and glycosidase inhibition evaluation of (3S,4S)-3-((R)-1,2-dihydroxyethyl)pyrrolidine-3,4-diol. Carbohydrate Research, 2016, 434, 33-36.	1.1	4
166	JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo. Cancer Chemotherapy and Pharmacology, 2016, 78, 971-982.	1.1	10
167	Design, synthesis, and preliminary evaluation of the biological activity of dithiocarbamate-3-epi-jaspine B hybrids. Medicinal Chemistry Research, 2016, 25, 3011-3020.	1.1	5
168	A new brominated chalcone derivative suppresses the growth of gastric cancer cells in vitro and in vivo involving ROS mediated up-regulation of DR5 and 4 expression and apoptosis. Toxicology and Applied Pharmacology, 2016, 309, 77-86.	1.3	22
169	Design, synthesis and biological evaluation of $[1,2,3]$ triazolo $[4,5-d]$ pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents. European Journal of Medicinal Chemistry, 2016, 124, 967-980.	2.6	63
170	Baicalin, a natural LSD1 inhibitor. Bioorganic Chemistry, 2016, 69, 129-131.	2.0	47
171	A Systematic Review of Histone Lysineâ€Specific Demethylase 1 and Its Inhibitors. Medicinal Research Reviews, 2015, 35, 1032-1071.	5.0	157
172	Design, Synthesis, and Structure–Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine–Thiourea Hybrids As Potent, Orally Active Antitumor Agents. Journal of Medicinal Chemistry, 2015, 58, 1705-1716.	2.9	139
173	Design and synthesis of novel 1,2,3-triazole–pyrimidine–urea hybrids as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1124-1128.	1.0	82
174	Synthesis, in vitro and in vivo anticancer activities of novel 4-substituted 1,2-bis(4-chlorophenyl)-pyrazolidine-3,5-dione derivatives. MedChemComm, 2015, 6, 1781-1786.	3.5	13
175	Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget, 2015, 6, 41809-41824.	0.8	41
176	Synthesis and anti-BVDV activity of novel $\hat{\Gamma}$ -sultones in vitro: Implications for HCV therapies. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2388-2391.	1.0	19
177	Synthesis and biological evaluation of coumarin–1,2,3-triazole–dithiocarbamate hybrids as potent LSD1 inhibitors. MedChemComm, 2014, 5, 650-654.	3.5	79
178	Design and synthesis of novel 1,2,3-triazole-pyrimidine hybrids as potential anticancer agents. European Journal of Medicinal Chemistry, 2014, 86, 368-380.	2.6	93
179	Triazoleâ€"Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration. Journal of Medicinal Chemistry, 2013, 56, 8543-8560.	2.9	198
180	Synthesis of 2,2â€Bisâ€ <i>C</i> â€functionalized Chain Glucosidâ€3â€ketals. Chinese Journal of Chemistry, 2012, 30, 195-198.	2.6	10

#	Article	IF	CITATIONS
181	Direct Resolution of the Enantiomers of Betaxolol and Related Intermediates, and Its Application. Chromatographia, 2010, 71, 987-991.	0.7	2
182	Microbial transformation of $5\hat{l}_{\pm}$, $6\hat{l}_{\pm}$ -epoxy- $3\hat{l}_{\pm}$ -hydroxy-16-pregnen-20-one by Trichoderma viride. Steroids, 2007, 72, 509-513.	0.8	5
183	Synthesis of New Chiral [2-(1-Hydroxyalkyl)pyrrolidino]methyl-ferrocenes and Application to the Catalytic Asymmetric Addition of Diethylzinc to Arylaldehydes. Chinese Journal of Chemistry, 2005, 23, 1443-1448.	2.6	5
184	Asymmetric synthesis of novel tetrahydroquinoline derivatives with a sugar building block and their bioactivities. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1821-1824.	1.0	19
185	Stereoselective Synthesis of New Higher Carbon Sugars from D-Xylose. European Journal of Organic Chemistry, 2004, 2004, 2103-2106.	1.2	18
186	Novel autoxidation and Michael addition of a butenolide-containing sugar leading to a C-branched-chain glucopyranosidulose, and X-ray structure of intermediates. Carbohydrate Research, 2003, 338, 1737-1743.	1.1	20
187	Stereoselective synthesis of 2,2-bis(C-branched-chain)glucopyranosid-3-ulose via an autoxidation–Michael addition reaction. Chemical Communications, 2003, , 2044-2045.	2.2	24
188	Stereoselective synthesis of 2-amino-2-deoxysugars: N-alkyl-D-allosamines. Organic and Biomolecular Chemistry, 2003, 1, 1641-1642.	1.5	21
189	A mild and selective method for cleavage of O-acetyl groups with dibutyltin oxide. Carbohydrate Research, 2002, 337, 1763-1767.	1.1	19